Last reviewed · How we verify
ccIIV4
ccIIV4 is a cell-culture-derived inactivated influenza vaccine that stimulates immune responses against multiple influenza virus strains.
ccIIV4 is a cell-culture-derived inactivated influenza vaccine that stimulates immune responses against multiple influenza virus strains. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | ccIIV4 |
|---|---|
| Also known as | Flucelvax |
| Sponsor | Vanderbilt University Medical Center |
| Drug class | Inactivated influenza vaccine |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
ccIIV4 is a quadrivalent inactivated influenza vaccine produced using cell culture technology rather than egg-based methods. It contains inactivated antigens from four influenza virus strains (two A subtypes and two B lineages) and works by inducing humoral and cellular immune responses to provide protection against seasonal influenza infection.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- Randomized Influenza Vaccine Evaluation of Immune Response (PHASE4)
- Immunogenicity of Influenza Vaccinations (PHASE4)
- Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults
- Influenza Vaccine Feasibility Study in Children With Persistent Asthma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ccIIV4 CI brief — competitive landscape report
- ccIIV4 updates RSS · CI watch RSS
- Vanderbilt University Medical Center portfolio CI